These authors suggested a therapeutic potential for receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibition in IBD patients, after demonstrating that RIPK1 prevented epithelial cell death and colitis development in NEMOIEC−KO mice [99]. Here, RIPK1 is linked to colitis.